The coronavirus vaccine developed by the biotechnology company Moderna has triggered “quick and strong” immune responses in all volunteers who received it in phase one of the research and could be ready by 2021.
The first results of Moderna’s research were published this Tuesday in the “New England Journal of Medicine” and in particular show that the vaccine triggers an immune response with mild side effects such as fatigue, chills, headache and pain. Muscle and pain at the injection site.
The vaccine, which was developed in collaboration with the US National Institutes of Health, is expected to begin the third phase of the study, the final phase of the research, on July 27 with 30,000 volunteers.
As Moderna said in a statement, “the company is on the right track to deliver about 500 million cans a year, and possibly up to a billion cans a year, by 2021”.
According to the World Health Organization (WHO), around 300 coronavirus vaccines are currently in the test phase.